3/24
04:57 pm
hrow
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030
Low
Report
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030
3/24
08:29 am
hrow
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth [TheStreet.com]
Medium
Report
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth [TheStreet.com]
3/24
08:15 am
hrow
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth
Medium
Report
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth
3/19
08:22 am
hrow
Harrow (HROW) had its "buy" rating reaffirmed by HC Wainwright. They now have a $70.00 price target on the stock.
Low
Report
Harrow (HROW) had its "buy" rating reaffirmed by HC Wainwright. They now have a $70.00 price target on the stock.
3/18
02:07 pm
hrow
Harrow (HROW) was downgraded by Nomura to "neutral".
Low
Report
Harrow (HROW) was downgraded by Nomura to "neutral".
3/18
12:25 pm
hrow
Harrow (HROW) had its "buy" rating reaffirmed by BTIG Research. They now have a $63.00 price target on the stock.
Low
Report
Harrow (HROW) had its "buy" rating reaffirmed by BTIG Research. They now have a $63.00 price target on the stock.
3/18
07:40 am
hrow
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting [Yahoo! Finance]
Low
Report
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting [Yahoo! Finance]
3/18
07:00 am
hrow
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting
Medium
Report
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting
3/17
02:03 pm
hrow
Harrow Emerging As Dominant Operator In U.S. Ophthalmic Market [Seeking Alpha]
Low
Report
Harrow Emerging As Dominant Operator In U.S. Ophthalmic Market [Seeking Alpha]
3/9
09:11 pm
hrow
Harrow Inc (HROW) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Expansions [Yahoo! Finance]
Low
Report
Harrow Inc (HROW) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Expansions [Yahoo! Finance]
3/5
07:56 am
hrow
Harrow (HROW) was downgraded by Zacks Research from "hold" to "strong sell".
Medium
Report
Harrow (HROW) was downgraded by Zacks Research from "hold" to "strong sell".
3/4
08:04 am
hrow
Harrow (HROW) had its price target lowered by Cantor Fitzgerald from $94.00 to $91.00. They now have an "overweight" rating on the stock.
Low
Report
Harrow (HROW) had its price target lowered by Cantor Fitzgerald from $94.00 to $91.00. They now have an "overweight" rating on the stock.
3/4
08:00 am
hrow
Harrow (HROW) had its price target raised by HC Wainwright from $69.00 to $70.00. They now have a "buy" rating on the stock.
Low
Report
Harrow (HROW) had its price target raised by HC Wainwright from $69.00 to $70.00. They now have a "buy" rating on the stock.
3/4
07:25 am
hrow
Harrow to Present at Leerink Partner's 2026 Global Healthcare Conference [Yahoo! Finance]
Low
Report
Harrow to Present at Leerink Partner's 2026 Global Healthcare Conference [Yahoo! Finance]
3/4
07:00 am
hrow
Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference
Low
Report
Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference
3/3
05:03 pm
hrow
Harrow (HROW) had its "outperform" rating reaffirmed by William Blair.
Low
Report
Harrow (HROW) had its "outperform" rating reaffirmed by William Blair.
3/3
02:33 pm
hrow
Harrow Shares Collapse, Another Opportunity? [Seeking Alpha]
Low
Report
Harrow Shares Collapse, Another Opportunity? [Seeking Alpha]
3/3
11:16 am
hrow
Harrow (HROW) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Harrow (HROW) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
3/3
07:00 am
hrow
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication
High
Report
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication
3/2
04:40 pm
hrow
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance [Yahoo! Finance]
High
Report
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance [Yahoo! Finance]
3/2
04:05 pm
hrow
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance
High
Report
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance
2/28
09:41 am
hrow
Harrow, Inc. (HROW): A Bull Case Theory [Yahoo! Finance]
Low
Report
Harrow, Inc. (HROW): A Bull Case Theory [Yahoo! Finance]
2/18
07:00 am
hrow
Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026
Low
Report
Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026
2/17
07:00 am
hrow
Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits
Medium
Report
Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits
2/4
06:44 am
hrow
Harrow (NASDAQ:HROW) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Harrow (NASDAQ:HROW) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.